# Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx

> **NCT04872686** · PHASE3 · COMPLETED · sponsor: **DR. MALA KHAN** · enrollment: 798 (actual)

## Conditions studied

- Virus Infection, RNA
- Effect of Drug
- Efficacy, Self

## Interventions

- **DRUG:** 0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient
- **DRUG:** 0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity
- **DRUG:** 0.6% PVP-I Oral and nasal spray to healthy volunteer
- **OTHER:** Oral and nasal spray by distilled water to control group

## Key facts

- **NCT ID:** NCT04872686
- **Lead sponsor:** DR. MALA KHAN
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-10
- **Primary completion:** 2021-05-25
- **Final completion:** 2021-05-30
- **Target enrollment:** 798 (ACTUAL)
- **Last updated:** 2022-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04872686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04872686, "Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04872686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*